#OncoAlert Important work by @RymaBenayed @MLadanyi in @CCR_AACR online now reviewing why RNA testing is critical for patients with #NSCLC in the important search for actionable driver alterations to guide proper therapy #LCSM
clincancerres.aacrjournals.org/content/early/…
@RymaBenayed @MLadanyi @CCR_AACR #OncoAlert The authors analyzed 254 patients with lung adenocarcinoma who were driver negative by MSK-IMPACT (DNA based NGS) and had enough tissue for RNA sequencing with ARCHER. 232 successfully sequenced and they identified 36 driver events or 15.5% of these patients! #LCSM
@RymaBenayed @MLadanyi @CCR_AACR The most common were #ROS1 (28%), #NRG1 (14%), #ALK (11%), #RET (8%) and #NTRK (8%). Patients able to receive targeted therapy had the expected good outcomes. @ros1cancer @EGFRResisters @ALKLungCancer
@RymaBenayed @MLadanyi @CCR_AACR @ros1cancer @EGFRResisters @ALKLungCancer These patients would have been deemed driver negative by DNA and would likely have received chemo/IO or pembro monotherapy. These are the patients less likely to derive benefit from IO; it is not possible to optimally manage patients unless the true molecular profile is known!
@RymaBenayed @MLadanyi @CCR_AACR @ros1cancer @EGFRResisters @ALKLungCancer Not unique to MSK-IMPACT. The assay picked up most of the events – but there will be gaps when you only use a DNA based approach, as outlined in the accompanying editorial by Dara Aisner @CUAnschutz
clincancerres.aacrjournals.org/content/early/…
@RymaBenayed @MLadanyi @CCR_AACR @ros1cancer @EGFRResisters @ALKLungCancer @CUAnschutz DNA NGS can miss events for various reasons: long introns (NTRK3, #NRG1), highly repetitive elements (#ROS1), non-canonical splice site variants (#METex14) or low tumor purity. Shows value of RNA seq. We favor dual DNA/RNA extraction up front when possible! #OncoAlert #LCSM
@RymaBenayed @MLadanyi @CCR_AACR @ros1cancer @EGFRResisters @ALKLungCancer @CUAnschutz RNA sequencing can add cost - but delivering the wrong therapy is much more costly - in every sense. Delivery of immunotherapy alone to a patient whose tumor harbors an ALK fusion will be an expensive and ineffective endeavor - costing both money and time. #LCSM
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.